Literature DB >> 15014639

Depression: Diagnosis and Management for the Primary Care Physician.

James M. Ferguson1.   

Abstract

BACKGROUND: Much has been learned in recent years about the diagnosis and treatment of depression, a serious, commonly overlooked psychiatric illness often seen initially by the primary care physician. The objective of this article is to review the diagnosis and treatment of depression in primary care practice.
METHOD: Relevant articles on depression were identified by a comprehensive MEDLINE search and classified into the following categories: diagnosis and screening, nonpharmacologic therapy, pharmacologic therapy, newer antidepressant agents, and maximizing antidepressant therapy. The importance to primary care practice was considered in determining the significance of each article reviewed.
RESULTS: Because no laboratory tests exist for depression and no biological markers can be measured routinely, the diagnosis of depression must be made with a number of reliable depression scales and questionnaires that can be completed quickly in the primary care setting. The considerable overlap between depressive and anxiety disorders further complicates an accurate diagnosis. Remission (i.e., absence of symptoms) is the ultimate goal of therapy for patients who have depressive symptoms.
CONCLUSION: Many patients can be treated safely and effectively for depression in the primary care setting with pharmacologic therapy, which, if completely successful, can lead to full remission of the disorder.

Entities:  

Year:  2000        PMID: 15014639      PMCID: PMC181135          DOI: 10.4088/pcc.v02n0504

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  21 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

Review 2.  Overview of antidepressants currently used to treat anxiety disorders.

Authors:  J P Feighner
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

3.  A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.

Authors:  R L Rudolph; A D Feiger
Journal:  J Affect Disord       Date:  1999-12       Impact factor: 4.839

Review 4.  Bupropion sustained release: a therapeutic overview.

Authors:  J R Davidson; K M Connor
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

5.  Strategies for counseling depressed patients by primary care physicians.

Authors:  D S Brody; T L Thompson; D B Larson; D E Ford; W J Katon; K M Magruder
Journal:  J Gen Intern Med       Date:  1994-10       Impact factor: 5.128

Review 6.  Pharmacology of antidepressants--characteristics of the ideal drug.

Authors:  E Richelson
Journal:  Mayo Clin Proc       Date:  1994-11       Impact factor: 7.616

7.  Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.

Authors:  J P Feighner; A R Entsuah; M K McPherson
Journal:  J Affect Disord       Date:  1998-01       Impact factor: 4.839

8.  The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.

Authors:  A Khan; G V Upton; R L Rudolph; R Entsuah; S M Leventer
Journal:  J Clin Psychopharmacol       Date:  1998-02       Impact factor: 3.153

Review 9.  Venlafaxine: a heterocyclic antidepressant.

Authors:  V L Ellingrod; P J Perry
Journal:  Am J Hosp Pharm       Date:  1994-12-15

10.  Recognition and treatment of depression in a primary care setting.

Authors:  C B Montano
Journal:  J Clin Psychiatry       Date:  1994-12       Impact factor: 4.384

View more
  1 in total

1.  The additive effects of depressive symptoms and polysubstance use on HIV risk among gay, bisexual, and other men who have sex with men.

Authors:  Kiffer G Card; Nathan J Lachowsky; Heather L Armstrong; Zishan Cui; Lu Wang; Paul Sereda; Jody Jollimore; Thomas L Patterson; Trevor Corneil; Robert S Hogg; Eric A Roth; David M Moore
Journal:  Addict Behav       Date:  2018-03-06       Impact factor: 3.913

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.